ArticleThe journal of headache and pain2021
Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
Michael Ament et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.